Capricor Therapeutics, Inc. (CAPR)

Market Cap	103.99M
Revenue (ttm)	2.55M
Net Income (ttm)	-29.02M
Shares Out	25.24M
EPS (ttm)	-1.18
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	83,363
Open	4.13
Previous Close	4.19
Day's Range	4.06 - 4.27
52-Week Range	2.81 - 6.58
Beta	4.09
Analysts	Buy
Price Target	16.83 (+308.5%)
Earnings Date	May 9, 2023

About CAPR

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company al...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Employees: 48
• Stock Exchange: NASDAQ
• Ticker Symbol: CAPR

Financial Performance

In 2022, CAPR's revenue was $2.55 million, an increase of 941.85% compared to the previous year's $244,898. Losses were -$29.02 million, 44.9% more than in 2021.

Analyst Forecast

According to 9 analysts, the average rating for CAPR stock is "Buy." The 12-month stock price forecast is $16.83, which is an increase of 308.50% from the latest price.

Price Target

$16.83

(308.50% upside)

Analyst Consensus: Buy